Cladribine, Cytarabine and Venetoclax for HR-MDS
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Arms / Cohorts
Experimental:MDS Relapsed Cohort: Cladribine + Cytarabine + Venetoclax + Azacitidine
Accepting patients
Experimental:MDS Chemotherapy Naive Cohort: Cladribine + Cytarabine + Venetoclax + Azacitidine
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.